Apollo Endosurgery (APEN) Prices 8.4M Share Common Stock Offering at $7.75/sh

Apollo Endosurgery, Inc. (NASDAQ: APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the pricing of its previously announced underwritten public offering. Apollo is selling 8,400,000 shares of its common stock at a public offering price of $7.75 per share for gross proceeds of approximately $65 million, before deducting underwriting discounts and commissions and offering expenses. All of the shares of common stock are being offered by Apollo. In addition, Apollo has granted the underwriters a 30-day option to purchase up to an additional 1,260,000 shares of common stock. The offering is expected to close on October 15, 2021, subject to customary closing conditions.

Piper Sandler, Cowen and Stifel are acting as the joint book-running managers for the proposed offering. Craig-Hallum and Lake Street are acting as co-managers for the offering.

The proposed offering is being made pursuant to a shelf registration statement on Form S-3, including a base prospectus, filed by Apollo with the Securities and Exchange Commission (the "SEC"), which was declared effective by the SEC on May 19, 2021. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement relating to the offering was filed with the SEC and is available on the SEC's website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus related to the offering may be obtained, when available, from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at [email protected]; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at [email protected]; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at [email protected].

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

You May Also Be Interested In

• Daré Bioscience prices $6M direct offering at $1.37 per share
• Silence Therapeutics closes $201M public offering of ADSs
• bioAffinity Technologies closes $4M private placement via pre-funded warrants